Associate Director, Toxicology (Watertown, MA - Onsite)

• Lead Research Areas: Lead and manage moderately complex research areas within toxicology to support the advancement of our discovery and development pipeline.
• CRO Oversight: Oversee preclinical toxicology studies at external contract research organizations (CROs), ensuring effective project management and scientific oversight.
• Study Initiation: Design nonGLP and GLP in vivo studies in rodent and non-rodent species, facilitate study initiation through contract execution, test article procurement, protocol development, and timeline commitment.
• Study Monitoring: Monitor ongoing studies to ensure appropriate conduct, accuracy, and timely completion; anticipate issues and address proactively with CRO staff; audit raw data and critically review all draft subreports and comprehensive main study report for completeness.
• Data Evaluation: Evaluate study data across multiple disciplines (anatomic pathology, clinical pathology, in-life parameters, etc.), interpret and integrate findings to assess compound toxicity, and prepare summaries for internal discussion.
• Safety Strategy: Collaborate with the Toxicology team and cross-functional project teams to develop safety strategies to advance Development Candidate compounds.
• Regulatory Contribution: Author initial drafts of toxicology-specific subsections of pre-IND, IND and IB filings and ensure GLP compliance (21 CFR Part 58).
• Scientific Partnership: Build and maintain strong collaborative relationships with research and development teams to achieve shared goals.

• Educational Background: DVM, PhD, and Diplomate of the American College of Veterinary Pathologists (DACVP).
• Leadership Experience: 5 years of direct or indirect management experience in toxicology within the pharmaceutical or biotechnology industry, including experience managing internal programs and external collaborations.
• Project Management: Demonstrated experience in leading and managing toxicology or related research projects from inception to completion.
• Cross-disciplinary Collaboration: Strong ability to work across disciplines and with external partners, fostering collaboration and scientific excellence.
• Scientific Knowledge: Education and hands-on training in animal sciences, including toxicology, pathology, and physiology, with direct experience in developmental and reproductive biology.
• Communication Skills: Excellent written and verbal communication skills, with a focus on clarity and precision.
• Data-Driven Thinking: Data-driven decision-making abilities with a focus on scientific integrity and transparency.

• Strategic Insight: Ability to anticipate scientific trends and adjust strategy to maintain Enanta’s leadership in drug discovery and development.
• Agility: Comfort navigating a dynamic environment and managing competing priorities while delivering high-quality work.
• Communication: Strong communication skills with the ability to articulate complex scientific ideas across functions and levels.

• Curiosity: You demonstrate an unrelenting desire to explore, question, and innovate.
• Respectful: You engage with colleagues and partners with professionalism and care.
• Empathy: You are compassionate, both in teamwork and when thinking about patient impact.
• Agility: You thrive in fast-paced environments and adapt quickly to changing circumstances.
• Team-Oriented: You embrace collaboration, understanding that success comes from collective efforts.
• Entrepreneurial Spirit: You are proactive, continuously seeking opportunities to improve and grow.

Please complete the application below and include the following attachments:

• Cover Letter
• CV / Resume
• Research Summary (if applicable)

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

Enanta Pharmaceuticals is an equal opportunity employer (EOE) with a commitment to diversity. All individuals, regardless of personal characteristics, are encouraged to apply. All qualified applicants will receive consideration for employment without regard to race, color, national origin, age, religious creed, gender, gender identity, sexual orientation, physical or mental disability, protected veteran status, or any other class protected by law.